<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author><author><style face="normal" font="default" size="100%">Koutalellis, G.</style></author><author><style face="normal" font="default" size="100%">Fragoulis, E.G.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Biochemistry</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopa Decarboxylase/*genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Staging</style></keyword><keyword><style  face="normal" font="default" size="100%">Prostatic Hyperplasia/blood/enzymology/genetics/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Prostatic Neoplasms/blood/*enzymology/*genetics/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">ROC Curve</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">14-15</style></number><volume><style face="normal" font="default" size="100%">41</style></volume><pages><style face="normal" font="default" size="100%">1140-9</style></pages><isbn><style face="normal" font="default" size="100%">1873-2933 (Electronic)0009-9120 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: L-Dopa decarboxylase (DDC) is a pyridoxal 5'-phosphate-dependent enzyme that was found to be involved in many malignancies. The aim of this study was to investigate the mRNA expression levels of DDC in prostate tissues and to evaluate its clinical utility in prostate cancer (CaP). METHODS: Total RNA was isolated from 118 tissue specimens from benign prostate hyperplasia (BPH) and CaP patients and a highly sensitive quantitative real-time RT-PCR (qRT-PCR) method for DDC mRNA quantification has been developed using the SYBR Green chemistry. LNCaP prostate cancer cell line was used as a calibrator and GAPDH as a housekeeping gene. RESULTS: DDC was found to be overexpressed, at the mRNA level, in the specimens from prostate cancer patients, in comparison to those from benign prostate hyperplasia patients (p&amp;lt;0.001). Logistic regression and ROC analysis have demonstrated that the DDC expression has significant discriminatory value between CaP and BPH (p&amp;lt;0.001). DDC expression status was compared with other established prognostic factors, in prostate cancer. High expression levels of DDC were found more frequently in high Gleason's score tumors (p=0.022) as well as in advanced stage patients (p=0.032). CONCLUSIONS: Our data reveal the potential of DDC expression, at the mRNA level, as a novel biomarker in prostate cancer.</style></abstract><accession-num><style face="normal" font="default" size="100%">18586020</style></accession-num><notes><style face="normal" font="default" size="100%">Avgeris, MargaritisKoutalellis, GeorgiosFragoulis, Emmanuel GScorilas, AndreasengResearch Support, Non-U.S. Gov't2008/07/01 09:00Clin Biochem. 2008 Oct;41(14-15):1140-9. doi: 10.1016/j.clinbiochem.2008.04.026. Epub 2008 Jun 10.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, Greece.</style></auth-address></record></records></xml>